Research Reports Coverage on Biotech Stocks -- Northwest Biotherapeutics, Radius Health, Spectrum Pharma, and Kite Pharma

Sep 12, 2016, 08:05 ET from Chelmsford Park SA

NEW YORK, September 12, 2016 /PRNewswire/ --

Biotechnology has seen some substantial declines since the start of this year due to political comments on pricing, which is expected to persist for an uncertain period of time. Some companies in the industry, however, signal recovery and growth potential given M&A activities and the development of new methodologies and platforms. This morning, has initiated research reports on the following equities: Northwest Biotherapeutics Inc. (NASDAQ: NWBO), Radius Health Inc. (NASDAQ: RDUS), Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI), and Kite Pharma Inc. (NASDAQ: KITE). These stocks research reports can be downloaded now by simply registering for free at:

Northwest Biotherapeutics  

Bethesda, Maryland headquartered Northwest Biotherapeutics Inc.'s stock declined 1.11%, finishing last Friday's session at $0.34. A total volume of 1.25 million shares was traded, which was above their three months average volume of 908,560 shares. The Company's shares are trading below their 50-day moving average by 22.00%. Additionally, shares of Northwest Biotherapeutics, which discovers and develops immunotherapy products to treat cancer in the US and internationally, have a Relative Strength Index (RSI) of 33.00.

On September 06th, 2016, Northwest Biotherapeutics announced that NASDAQ has accepted NW Bio's proposed remediation plan to resolve NASDAQ's finding, previously disclosed by the company, that NW Bio failed to comply with certain NASDAQ listing rules with regard to certain securities issuances to Cognate BioServices, Inc. As a result of this acceptance, NASDAQ has notified the company that it has regained compliance with these rules, and this matter is now closed. Your complete research report on NWBO can be retrieved for free at:

Radius Health  

On Friday, shares in Cambridge, Massachusetts headquartered Radius Health Inc. ended the session 4.21% lower at $53.87. The stock recorded a trading volume of 980,873 shares, which was above its three months average volume of 841,420 shares. The Company's shares have gained 3.66% in the last month and 47.03% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 10.51% and 29.31%, respectively. Moreover, shares of Radius Health, which focuses on developing novel therapeutics for patients with osteoporosis and other serious endocrine-mediated diseases in the US, have an RSI of 52.27.

On August 16th, 2016, Radius Health announced that positive results from the Phase 3 ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpoints) trial were published in the Journal of the American Medical Association (JAMA). This landmark trial enrolled 2,463 patients to evaluate the safety and efficacy of investigational drug Abaloparatide for the treatment of postmenopausal women with osteoporosis. The ACTIVE results showed that patients treated with daily Abaloparatide for 18 months had a significantly greater reduction in the incidence of new vertebral fractures (p < 0.001) and non-vertebral fractures (p = 0.049) compared to placebo. RDUS free report is just a click away at:

Spectrum Pharma  

Henderson, Nevada headquartered Spectrum Pharmaceuticals Inc.'s stock dropped 1.82%, to close the day at $5.38 with a total volume of 748,793 shares traded. The Company's shares are trading 11.97% below their 200-day moving average. Shares of the Company, which develops and commercializes oncology and hematology drug products, have an RSI of 35.37.

On August 16th, 2016, Spectrum reported that total product sales were $30.9 million in Q2 2016. Spectrum recorded net loss of $24.3 million, or $(0.35) per basic and diluted share, in the three-month period ended June 30th, 2016, compared to net loss of $2.3 million, or $(0.04) per basic and diluted share in the comparable period in 2015. Total research and development expenses were $14.3 million in the quarter compared to $9.6 million in the same period in 2015. Selling, general, and administrative expenses were $27.6 million in the quarter compared to $22.6 million in the same period in 2015. Sign up for your complimentary research report on SPPI at:

Kite Pharma  

Shares in Santa Monica, California headquartered Kite Pharma Inc. recorded a trading volume of 725,213 shares. The stock ended Friday's session at $56.73, sliding 6.97%. The Company's shares have gained 10.58% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 2.40% and 6.45%, respectively. Furthermore, shares of Kite Pharma, which focuses on the development and commercialization of novel cancer immunotherapy products, have an RSI of 46.05.

On August 8th, 2016, Kite Pharma reported that revenue was $4.8 million for Q2 2016 compared to revenue of $4.4 million in the year ago period. Research and development expenses were $47.4 million for Q2 2016, and include $8.5 million of non-cash stock-based compensation expense. Net loss was $64.3 million, or $1.31 per share, for Q2 2016. As of June 30th, 2016, Kite had $531.1 million in cash, cash equivalents, and marketable securities. Register for free on and download the latest research report on KITE at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA